A twice-yearly injection has the potential to transform the way to deliver HIV prevention to people who need and want it most. It is the first big trial to reduce HIV infections to zero.
According to a statement released by Janssen Pharmaceuticals, the makers of the vaccine that was under phase 3 study, an independent data and safety monitoring board had reviewed the trial data and found that the regimen did not meet the pre-defined criteria for efficacy and recommended that the study be stopped and trial participants informed.
The drug was only approved by the U.S. Food and Drug Administration (FDA) on Monday. Dr. Mitchell Warren told a meeting attended by journalists from Africa that timelines have already been set between the necessary approvals and global access.
Johnson & Johnson and partners today announced that the Imbokodo study or the HVTN 705/ HPX2008, did not significantly reduce the overall risk of HIV acquisition among over 2,600 women.
